Stryker (SYK): The Demographic Trade Nobody Can Cancel

Most investment themes come with an expiration date. Rate cycles turn. Consumer trends reverse. A competitor shows up with a better product. You know the drill.

The aging of America is not one of those themes.

What the Scoreboard Says

Stryker posted $25.1 billion in full-year 2025 revenue – up 11.2% from 2024. Orthopedics alone came in at $9.5 billion for the year. MedSurg and Neurotechnology added another $15.6 billion, a 15.7% jump year over year. Net earnings hit $3.2 billion, a 55.5% increase versus the prior year. That’s not a fluke quarter. That’s a machine running at altitude.

Management is guiding for 8% to 9.5% full-year sales growth in 2026. Analyst consensus EPS forecast for next year sits around $12.74, compared to $8.49 last year. The stock has pulled back roughly 24% over the past twelve months – which is either a warning sign or a setup, depending on how you think about the next decade.

I lean toward setup. Here’s why.

The Demand That Doesn’t Negotiate

Baby boomers – born between 1946 and 1964 – number roughly 73 million in the U.S. The oldest are approaching 80. The youngest are pushing 60. By 2030, every single one of them will be 65 or older, meaning one in five Americans will be a senior citizen. That’s not a projection with a lot of wiggle room. It’s arithmetic.

Aging drives orthopedic volume in a way that’s almost mechanical. Joints wear out. Cartilage thins. Hips and knees that got someone through 40 years of work, exercise, and general living eventually need to be replaced. Studies consistently tie roughly 20% of healthcare spending growth directly to population aging. That money flows somewhere – and a big chunk of it flows through surgical suites, and right into Stryker’s revenue line.

Slight tangent, but it matters: this isn’t just a U.S. story. Global aging trends are accelerating across Europe, Japan, and parts of Southeast Asia simultaneously. Stryker operates internationally, which means the addressable market for orthopedic hardware isn’t contracting anytime soon.

How the Business Actually Works

Stryker makes implants, surgical instruments, robotic surgery systems (the Mako platform), and hospital equipment. The orthopedic segment – hips, knees, trauma fixation – is the part of the business most directly tied to the boomer tailwind. But the MedSurg and Neurotechnology side, which covers endoscopy, medical equipment, and neurovascular products, has been growing faster and now accounts for the majority of total revenue.

The Mako robotic surgery platform deserves a mention here. It’s a competitive moat. Surgeons trained on Mako tend to stay on Mako. Hospital systems that invest in the platform don’t switch. That kind of installed-base stickiness is what makes Stryker’s recurring revenue more durable than a lot of med-tech peers.

Stryker also put roughly $1.62 billion into R&D in 2025 and completed approximately $5 billion in acquisitions – including Inari Medical, which expands its vascular portfolio into venous thromboembolism treatment. The company is not standing still while demographics do the heavy lifting.

The Numbers Worth Tracking

• FY2025 revenue: $25.1B (+11.2% YoY)
• Orthopedics segment: $9.5B (+4.3% YoY; organic growth 9.3%)
• MedSurg & Neurotechnology: $15.6B (+15.7% YoY)
• Gross profit margin: ~63.9% (FY2025)
• Net earnings: $3.2B (+55.5% YoY)
• R&D spend: $1.62B
• Cash and equivalents: $4.1B
• Total debt: $15.9B (elevated post-acquisition)
• 2026 sales guidance: +8% to +9.5%
• 3-year forward revenue CAGR (analyst consensus): ~7.7–7.9%

The debt load is real and worth watching. Stryker issued $3.0 billion in new senior notes in 2025 and carries $15.9 billion in total debt. That’s the cost of being aggressive on M&A. It’s manageable at current cash flow levels – but it does mean the balance sheet is not pristine right now.

Bull, Base, Bear

• Bull: Demographics compound for 10+ years, Mako adoption accelerates, Inari integration adds a high-growth vascular leg, margins expand, EPS hits $14+ by 2028. Stock re-rates toward $400.
• Base: Mid-single-digit organic growth continues, debt gets steadily paid down, earnings grow 12–15% annually in line with consensus. Stock trades in the $310–$360 range over the next 18 months.
• Bear: Hospital capex freezes in a recession, pricing pressure intensifies, debt servicing costs bite into free cash flow, and the stock stays range-bound or drifts lower. The demographic thesis is intact – but valuation doesn’t expand.

Cheap Investor Scorecard

• Demographic tailwind: durable and multi-decade – check
• Revenue growth consistency: 10%+ over 3 years – check
• Gross margins above 63%: competitive moat confirmed – check
• Robotic surgery installed base (Mako): high switching costs – check
• Diversified beyond orthopedics (MedSurg, Vascular): check
• R&D investment: $1.62B annually – check
• Dividend payer: $1.28B paid in 2025 – check
• Debt load post-Inari acquisition: elevated – monitor
• 2026 guidance: 8–9.5% growth, raised mid-year – check
• Stock down ~24% from highs: potential entry window – check

Here’s where I land on this. If you believe 73 million aging Americans need more orthopedic procedures over the next 10 to 15 years – and the data says they will – then Stryker is one of the cleanest expressions of that trade in public markets. The pullback brings the entry point to a more interesting place. The debt is worth watching. But the demand curve? That one’s already written.

The question isn’t whether the trend is real. It’s whether you’re positioned before the wave or chasing it.

– The Cheap Investor